| Size | Price | Stock | Qty |
|---|---|---|---|
| 59mg(100 mM * 1 mL in Water) |
|
||
| Other Sizes |
| Targets |
6-Me-ATP targets glycogen synthase kinase 3 (GSK3) by serving as a phosphate group donor for GSK3β-catalyzed phosphorylation. As an N6-modified ATP derivative, it exhibits strong binding affinity for GSK3, making it a useful tool for studying kinase-substrate interactions. The compound's modification at the N6 position of the adenine ring may alter its interaction with the ATP-binding pocket of kinases, providing insights into the structural requirements for nucleotide binding and phosphorylation catalysis. It is used in proteome-wide characterizations of ATP-binding capabilities of kinases.
|
|---|---|
| ln Vitro |
In vitro, 6-Me-ATP shows excellent binding affinity to GSK3 and serves as the phosphate group donor for GSK3β-catalyzed phosphorylation of its substrate peptide. As an N6-modified ATP derivative, it is used to study kinase-substrate interactions and phosphorylation mechanisms. The compound has been characterized in proteome-wide studies to investigate the binding capabilities of kinases. Its modified structure allows researchers to probe the specificity and selectivity of ATP-binding pockets in various kinases. Detailed in vitro characterization data are available in the primary literature.
|
| ln Vivo |
In vivo studies of 6-Me-ATP are limited in publicly available literature, as the compound is primarily used as a biochemical tool for in vitro kinase assays rather than as a therapeutic agent. As an ATP analog, it is not typically administered in vivo due to its role as a phosphate donor and its likely rapid metabolism. The compound is used in research settings to study kinase-substrate interactions and phosphorylation mechanisms. No specific in vivo efficacy data or animal model studies have been reported.
|
| Enzyme Assay |
For GSK3β kinase activity assays using 6-Me-ATP as the phosphate donor, recombinant human GSK3β enzyme is incubated with peptide substrates and varying concentrations of 6-Me-ATP in appropriate reaction buffer. Kinase activity is measured by quantifying substrate phosphorylation using radioactive [γ-33P]-labeled 6-Me-ATP or by detecting phosphorylated product using mass spectrometry or antibody-based methods. The Km and Vmax for 6-Me-ATP can be determined from Michaelis-Menten kinetics. Assays are performed in triplicate with appropriate vehicle controls and ATP as a reference phosphate donor.
|
| Cell Assay |
For in vitro cellular assays, 6-Me-ATP is not typically used as a cell-permeable compound due to its highly charged phosphate groups. It is primarily used in cell-free kinase assays rather than in intact cell models. For studies requiring intracellular ATP analog delivery, specialized techniques such as microinjection or permeabilized cell systems may be employed. Researchers should consult the primary literature for specific protocols involving cellular delivery of modified nucleotides. Each concentration is tested in replicate with appropriate controls.
|
| Animal Protocol |
For in vivo animal studies of 6-Me-ATP, no specific published protocols are available. As an ATP analog with multiple phosphate groups, the compound is unlikely to be suitable for in vivo administration due to poor cell permeability and rapid metabolism. The compound is primarily used as a research tool in biochemical assays rather than for in vivo pharmacological studies. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-Me-ATP are characteristic of a nucleotide analog. The compound has a molecular weight of 521.21, formula C11H18N5O13P3, and CAS number 3130-39-0. Purity: >95% HPLC. Salt form: Sodium. Appearance: 10 mM aqueous solution of pH 7.6. Storage temperature: -70°C. Stability and solubility advice: information concerning product stability, particularly in solution, has rarely been reported. Specific pharmacokinetic parameters such as half-life, clearance, and bioavailability are not applicable for this biochemical reagent.
|
| Toxicity/Toxicokinetics |
According to available safety information, 6-Me-ATP is intended for research purposes only and is not for human use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
6-Me-ATP (N6-Methyl-ATP) is an N6-modified ATP derivative that shows excellent binding affinity to GSK3 and serves as a phosphate donor for GSK3β-catalyzed phosphorylation. It has a molecular weight of 521.21 and formula C11H18N5O13P3. The compound is used in proteome-wide characterizations of kinase binding capabilities. It is for research use only with no clinical development or regulatory approvals reported.
|
| Molecular Formula |
C11H18N5O13P3
|
|---|---|
| Molecular Weight |
521.21
|
| Exact Mass |
521.011
|
| CAS # |
3130-39-0
|
| Related CAS # |
6-Me-ATP trisodium
|
| PubChem CID |
23279502
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
816
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C(OP(=O)(O)OP(O)(=O)OP(O)(O)=O)[C@H]1O[C@@H](N2C3C(=C(N=CN=3)NC)N=C2)[C@H](O)[C@@H]1O
|
| InChi Key |
LCQWKKZWHQFOAH-IOSLPCCCSA-N
|
| InChi Code |
InChI=1S/C11H18N5O13P3/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(18)7(17)5(27-11)2-26-31(22,23)29-32(24,25)28-30(19,20)21/h3-5,7-8,11,17-18H,2H2,1H3,(H,22,23)(H,24,25)(H,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1
|
| Chemical Name |
[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9186 mL | 9.5931 mL | 19.1861 mL | |
| 5 mM | 0.3837 mL | 1.9186 mL | 3.8372 mL | |
| 10 mM | 0.1919 mL | 0.9593 mL | 1.9186 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
